Preprint Article Version 1 This version is not peer-reviewed

p53 Reaction to Cellular Stress Maximizes Apoptosis in Glioblastoma

Version 1 : Received: 29 January 2019 / Approved: 30 January 2019 / Online: 30 January 2019 (13:03:22 CET)

How to cite: Ho, C.; Pao, Y.; Chen, H.; Zhu, W.; Lin, R.; Chu, C.W.; Loh, J.K.; Hong, Y.; Wang, C. p53 Reaction to Cellular Stress Maximizes Apoptosis in Glioblastoma. Preprints 2019, 2019010315 (doi: 10.20944/preprints201901.0315.v1). Ho, C.; Pao, Y.; Chen, H.; Zhu, W.; Lin, R.; Chu, C.W.; Loh, J.K.; Hong, Y.; Wang, C. p53 Reaction to Cellular Stress Maximizes Apoptosis in Glioblastoma. Preprints 2019, 2019010315 (doi: 10.20944/preprints201901.0315.v1).

Abstract

In prostate cancer, p53 maximizes apoptosis in response to severe DNA damage, not DNA replication stress. Here, we examined the apoptotic response of two glioblastoma cells, p53-wild type U87 and a p53-mutated T98G cell, for the same stresses. We ascertained that p53 intensified apoptosis in response to severe DNA damage, not DNA replication stress in glioblastoma. We further asked if p53-mediated apoptosis can be induced by cellular stress other than severe DNA damage. We analyzed two compounds, bortezomib and vorinostat, respective inhibitors of 26S proteasome and histone deacetylase, to evaluate their capacity to activate p53-mediated apoptosis. The cellular stress incited by bortezomib, not vorinostat, activated p53-mediated apoptosis. Next, we asked if the cellular stress generated by combining the two compounds had a synergistic effect on apoptosis. Our results demonstrated that doxorubicin with bortezomib or CFS-1686, or bortezomib with vorinostat have a significant synergistic effect on apoptosis only in p53-wild type cell. Under high stress, p53 translocates from cytosol into the nucleus to cause apoptosis possibly. Together, p53 maximizes apoptosis for cellular stress caused by severe DNA damage, disruption of protein turnover, and for the stress induced by drug combination including doxorubicin with bortezomib or CFS-1686, and bortezomib with vorinostat.

Subject Areas

glioblastoma; p53; apoptosis; doxorubicin; bortezomib; vorinostat.

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.